The world’s deadliest infectious disease is on the rise in the US

Key event: 207 members of Archbishop Riordan High School tested positive for latent TB, with 4 confirmed active and 3 suspected active cases as of Feb 24. Context: approximately 13 million people in the US have latent TB; TB preventative treatment (TPT) costs about $857 for a 3–4 month course while treating active TB costs >50x that, drug-resistant TB treatment can be ~$154,000 per patient, and US treatment spending would exceed $11B annually if rates matched current global averages. Implication: rising TB incidence, COVID-era diagnostic delays, drug shortages and public-health funding cuts increase epidemiological and fiscal risk, supporting the case for sustained investment in screening, treatment access and R&D to avoid costly outbreaks and resistance.

Analysis

Diagnostics and manufacturing are the obvious industrial reflex points when a slowly progressive airborne disease re-emerges in high-income settings: molecular platforms, cartridge/consumable suppliers, and CDMOs see durable demand because testing is recurring and scale-insensitive to short-term case churn. Expect diagnostic OEMs that own closed-system molecular cartridges to capture >70% of incremental margin on volume growth because reagent and cartridge economics drive recurring revenue and high gross margins.

A meaningful tail risk is a sustained uptick in multidrug-resistant (MDR) cases that forces adoption of longer, bespoke regimens and orphan drugs; that scenario puts premium pricing power in the hands of specialty pharma and manufacturers of second‑line agents and injectables, and would likely push procurement cycles and regulatory fast-tracking—timeline: early signal within 6–18 months, full market re‑pricing over 2–4 years. Conversely, a near‑term reversal could arrive from renewed large-scale funding (multilateral or US appropriation) or an accelerated vaccine approval pathway—both would shift dollars from downstream acute care into prevention, altering the beneficiary list.

For portfolio construction, prioritize cash-flowable diagnostics and contract manufacturing exposures with optionality on government and philanthropic procurement contracts, size positions for regulatory and funding binary risks, and hedge with caps or pairs to protect against policy-driven reversals. Monitor three high-signal catalysts: federal/state public-health emergency declarations (weeks–months), FDA breakthrough/regulatory actions on TB drugs or vaccines (6–24 months), and global procurement commitments from large donors (Global Fund/USAID) which materialize over 6–18 months.

Key Decisions for Investors

• Buy Danaher (DHR) — tactical 6–12 month call‑spread (buy 12‑month 5% OTM calls, sell 12‑month 20% OTM calls) to express recurring molecular diagnostics upside from increased latent/active screening; target +15–25% vs premium paid, max loss = premium (~100% of option spend).
• Buy Catalent (CTLT) or Lonza (LZAGY) — 12–24 month LEAPS (or outright small equity position) to capture upside if vaccine/antibiotic manufacturing contracts accelerate; asymmetric payoff if one large procurement deal (> $100M) is awarded — aim for 2–3x upside vs downside limited to equity drawdowns in severe macro downturns (20–35%).
• Pair trade: long Roche ADR (RHHBY) 9–18 month calls vs short TEVA (TEVA) or another large generic antibiotic producer — trade reflects premium for integrated diagnostics + vaccine platform vs commoditized generics facing pricing pressure and supply‑chain competition; target spread appreciation of ~15% in 12 months, hedge size to limit net delta.
• Overweight municipal health‑related credits or a muni healthcare allocation (6–24 months) sized as a defensive hedge against healthcare system stress; these typically benefit from state/federal backstops if outbreaks force increased public‑health spending. Risk: policy reprioritization could blunt the bid and compress returns.